ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the appointment of Stephen Doyle as Head of China. Mr Doyle will assume the role in February 2018 and will be based at ASLAN’s offices in Shanghai.
Mr Doyle joins ASLAN’s senior management team from Boehringer Ingelheim, where he was most recently Vice President and Head of Speciality Care for China. At Boehringer Ingelheim, he led the marketing and sales for oncology, biosimilars and rare diseases in China, launching Giotrif® for non-small cell lung cancer and securing the approval for Ofev® for idiopathic pulmonary fibrosis. In his new role, Mr Doyle will oversee ASLAN’s operations and pipeline development in China.